Eulalia Jiménez

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4

Dave Singh, Patricia Guller, Fred Reid et al. · European Respiratory Journal · 2025 · 48 citations

Medicine, Immunology, Pharmacotherapy +17

A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease

Fred Reid, Dave Singh, Muna Albayaty et al. · Clinical Pharmacology & Therapeutics · 2023 · 42 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

Dave Singh, Jutta Beier, Carol Astbury et al. · European Respiratory Journal · 2021 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β₂‐agonist

Wolfgang Timmer, Èric Massana, Eulalia Jiménez et al. · The Journal of Clinical Pharmacology · 2014 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

Jutta Beier, Helena Pujol, Beatriz Seoane et al. · BMC Pulmonary Medicine · 2016 · 14 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17